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a b s t r a c t
Latin America is the region with the third most AIDS-related cryptococcal meningitis infec-
tions globally. Highly active antiretroviral therapy (HAART) has reduced the number of
infections; however, the number of deaths and the case-fatality rate continues to be unac-
ceptable. In this review, we focus on the burden of AIDS-related cryptococcosis in Latin
America anddiscuss potential strategies to reduce earlymortality fromCryptococcus. In this
review, we highlight the importance of: (1) earlier HIV diagnosis and HAART initiation with
retention-in-care to avoid AIDS; (2) pre-HAART cryptococcal antigen (CRAG) screening with
preemptive ﬂuconazole treatment; (3) better diagnostics (e.g. CRAG testing); and (4) optimal
treatment with aggressive management of intracranial pressure and induction therapy withiagnosis
reatment
ortality
atin America
antifungal combination. Implementationof these strategies can reduce cryptococcal-related
deaths, improve care, and reduce healthcare costs.
ência emTreinamento emDST/AIDS fromSão Paulo, showed a
progressive and important declining of notiﬁed cases of AIDS-
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDntroduction
ryptococcal meningitis affects approximately 1,000,000 peo-
le in the world each year and results in more than 400,000
eaths within three months after disease.1 Sub-Saharan
frica had the highest burden with an estimated yearly cryp-
ococcal meningitis cases: 720,000, but Latin America is the
hird global region with most cases with 54,400 estimated
ryptococcal meningitis cases annually. Most published stud-
es regarding cryptococcalmeningitis have been reported from
ub-Saharan Africa, South Asia, and Southeast Asia,1–6 and
ata are scarce from Latin America.
∗ Corresponding author at: Departamento de Neurologia, Instituto de In
E-mail address: josevibe@gmail.com (J.E. Vidal).
413-8670 © 2013 Elsevier Editora Ltda.
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Este é um artigo Open Access sob a licençaAcquired immunodeﬁciency syndrome (AIDS)-associated
cryptococcal meningitis has decreased dramatically in high-
income countries in the highly active antiretroviral therapy
(HAART) era.7–9 However, the impact of HAART in reducing
cryptococcosis appears to be less in low and middle-income
countries with suboptimal access to HAART.10–12 Some stud-
ies suggest a declining number of cases in Brazil.10,13 Data
obtained fromtheEpidemiologyService of theCentrodeRefer-fectologia Emilio Ribas, São Paulo, SP, Brazil.
related extrapulmonary cryptococcosis during the HAART era.
Fig. 1 displays the decline in reported cases from 1982 to 2010
 de CC BY-NC-ND
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Fig. 1 – Number of cases of AIDS-related extrapulmonary
cryptococcosis cases. Sao Paulo, 1982–2010. Source: Base
Integrada Paulista de Aids (BIPAIDS) – Cooperac¸ão Técnica
PEDST/Aids-SP e Fundac¸ão SEADE, MS/SVS/Departamento
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Fig. 2 – Case-fatality rate of AIDS-related extra-pulmonary
cryptococcosis. Sao Paulo, 1982–2010. Source: Base
Integrada Paulista de Aids (BIPAIDS) – Cooperac¸ão Técnica
PEDST/Aids-SP e Fundac¸ão SEADE, MS/SVS/Departamento
Nacional de DST, Aids e Hepatites Virais.Nacional de DST, Aids e Hepatites Virais.
with 500 reported cases in 1992 and declining to only 82 cases
in 2010 reported from São Paulo. This is in the setting of a
well-structured HAART access. Certainly, the magnitude of
this result cannot be generalized to all cities or rural regions
in Brazil.14
Currently, cryptococcal meningitis is not an uncommon
complication in Brazil and other Latin American countries.
In this region, cryptococcosis represents the main cause of
opportunistic meningitis,15–18 and the mortality continues
to be unacceptably high (∼55%).1 Cities in Latin America
are very heterogeneous, and populations have substan-
tial socioeconomic disparities. In this scenario, the human
immunodeﬁciency virus (HIV) epidemic and opportunistic
infections disproportionally affect persons with lower socio-
economic status.
In this review, we discuss the mortality of AIDS-related
cryptococcal meningitis in Latin America, mortality in high
versus low and middle-income settings, prognostic fac-
tors associated with mortality, and strategies to reduce
cryptococcal-related mortality in the region.
Mortality of AIDS-related cryptococcal
meningitis in Latin America
There is limited information about case-fatality rate of
HIV-infected patients with cryptococcal meningitis in Latin
America in routine practice where amphotericin B is available
but not 5-ﬂucytosine (5-FC) and where combination induction
therapy with amphotericin and ﬂuconazole is yet infrequent.Data from the Epidemiology Service of the Centro de
Referência em Treinamento em DST/AIDS from São Paulo
show a consistent decline in notiﬁed cases of extrapulmonary
cryptococcosis-related deaths among AIDS patients during
the HAART era (Fig. 1). In addition, there has been a reduc-
tion in the case-fatality rate of extrapulmonary cryptococcosis
from >90% in the pre-HAART era to ∼40% in the HAART-era
(Fig. 2). Nevertheless, the burden of cryptococcal deaths con-
tinues.
In unselected retrospective hospital-based studies per-
formed in Brazil and Argentina, the case fatality rates have
ranged from 30% to 63%.19–24 In most of these studies
increased intracranial pressure (ICP) was not systematically
treated. A recent prospective hospital-based study performed
inBrazil reported a case fatality rate of 50%among131patients
between 1998 and 2010.25 Conversely, two prospective studies
reported lower mortality. The ﬁrst, a Peruvian study treating
patients with amphotericin B plus aggressive management of
ICP in the setting of a research study, the 10-week mortality
was 19%.26 The second, a Brazilian non-published prospective
study with 34 patients performed in the HAART era in which
all cases received amphotericin B plus aggressive manage-
ment of ICP, the 10-week mortality was 26%.27 Taken together,
these studies conﬁrm that acute mortality of AIDS-related
cryptococcal meningitis is high in Latin America. The mor-
tality is similar to 24–50% reported in interventional studies
carried out in Africa and Asia.28–31 In high resource countries,
mortality ranges from 9% to 25%.32–37 Interestingly, a recent
Italian study reported a 10-week mortality of only 1 (2.5%) of
40 persons with cryptococcal meningitis.38 Thus, improved
outcomes are possible.
Mortality in high-income versus low and
middle-income countriesAll countries in Latin America are classiﬁed as low or middle-
income. The differences in outcome between Latin America
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nd high-income countries have several potential explana-
ions.
First, late testers and late presenters with HIV infection
re more frequent in Latin America. Countries from Latin
merica present heterogeneous public health system and
opulation showing substantial socioeconomic disparities.
n this scenario, the human immunodeﬁciency virus (HIV)
pidemic and opportunistic infections affect predominantly
eople living in poverty with limited access to timely and for-
al medical care.13 A cross-sectional analysis performed of
047 HIV-infected HAART-naive patients at six sites in Latin
merica and the Caribbean reported 55% of late testers and
5% of late presenters, as deﬁned as presenting with CD4<200
ells/L.39 Another multi-cohort study with 5152 HIV-infected
AART-naïve patients at seven sites in Latin America and
he Caribbean reported 76% with late HIV diagnoses.40 This
revalence is nearly twice as high as that observed in high-
ncome settings (for example, 15-38% in Europe)41 and conﬁrm
he highly prevalent rate of late presenters and consequently
ate HAART initiation in Latin America. Consistently, low CD4
ount at HAART initiation and more advanced disease con-
titutes strong predictors of mortality in the ﬁrst year of
AART.40
Second, cryptococcal meningitis usually reveals HIV-
nfection in most settings.8,38,42 However, an additional
cenario reported in Latin America is that a signiﬁcant propor-
ionof patientswith cryptococcalmeningitis are aware of their
IV-status prior to admission (with or without prior HAART
se).24,25,27 This ﬁnding suggests continued missed opportu-
ities to initiate or maintain HAART with persistent barriers
o adherence and retention-in-care of a subset of patients.
Third, severe immunosuppression (also frequent in high-
ncome countries) but particularly concomitant anemia,
alnutrition, and severe cryptococcal meningitis are com-
on in Latin America.24 The delay in presentation with
iagnosis only when cryptococcal meningitis is advanced
s common.24,43 This is evident by the increased propor-
ions of patients presenting with neurologic complications in
esource-limited setting.42,44
Fourth, rapid diagnosis is paramount to optimizing sur-
ival; however, diagnosis is difﬁcult when optimum laboratory
upport is unavailable in most Latin American facilities.
lthough larger urban centers have a reasonable laboratory
nfrastructure, the availability of a timely diagnosis is highly
ariable by country and within country throughout Latin
merica.
Fifth, optimal medical management is not frequently
tilized. Combination antifungal induction therapy and
tilization of adequate measures to control of ICP are hetero-
eneous in routine practice. Combination antifungal therapy
sing amphotericin B plus a second adjunctive agent (e.g. 5-
C or high-dose ﬂuconazole 800-1200mg/day in divided doses)
as been associated with improved early fungicidal activ-
ty and with less mycological treatment failure.37,45–47 Early
ungal clearance from the cerebrospinal ﬂuid (CSF) is asso-
iated with 2-week and 10-week survival.29 Additionally, ICP
anagement is likely suboptimal in routine practice. Even in
he United States of America, frequent major deviation from
ptimal care with respect to increased ICP management was
eported in a retrospective study of routine care from two3;17(3):353–362 355
tertiary care facilities in Washington, D.C.48 While no ran-
domized controlled trial has been performed to validate ICP
management, cross-comparison of studies using similar anti-
fungal treatment regimens suggest there likely is 20–25%
improvement in survival with aggressive ICP control. ICP
management should be viewed as an integral component of
cryptococcosis treatment.
Prognostic factors associated with mortality
Several risk factors for treatment failure or mortality have
been reported elsewhere for AIDS-associated cryptococcal
meningitis.24,29,37,49,50 These risk factors are likely relatively
universal and applicable in Latin America. The major risk fac-
tors for mortality include: fungal burden (i.e. assessable by
quantitative microscopy, quantitative cultures, and/or cryp-
tococcal antigen titers), rate of fungal clearance, altered
mental status, paucity ofCSFWBCpleocytosis, abnormal brain
imaging, elevated ICP at admission (which is uncontrolled),
persistently elevated ICP, disseminated infection, and dura-
tion of antecedent symptoms.
Strategies to reduce mortality and morbidity
due to AIDS-related cryptococcal meningitis
Lawn et al. reviewed a number of strategies to reduce early
mortality and morbidity during HAART.51 A similar approach
can be taken to reduce the mortality and morbidity due to
cryptococcal meningitis in Latin America. Potential key points
to reduce mortality and morbidity are shown in Table 1. The
strategies include: (1) early HIV diagnosis and treatment; (2)
screening and preemptive treatment for subclinical crypto-
coccosis; (3) optimized diagnosis of cryptococcal meningitis;
and (4) optimized treatment of cryptococcal meningitis.
Early HIV diagnosis and treatment
Late HIV presenters have an increased risk of mortality and
morbidity, compared with patients who present early.41 Thus,
earlier HIV diagnosis and treatment are the most impor-
tant and cost-effective preventive strategies to reduce the
incidence and high mortality associated with cryptococcal
meningitis.43 In Latin America, nearly 42% of people eligible
for treatment were able to access HAART in 2009.52 Yet, con-
tinuation of HAART and avoiding HAART discontinuations are
of major relevance. Reinforcing public health systems at the
national and local level is necessary to obtain these challeng-
ing objectives in Latin America. Special focus must be offered
to marginalized populations (e.g. commercial sex workers,
men who have sex with men, injection drug users, and pris-
oners).
Pre-antiretroviral therapy careLinkage of testing to HIV care (engagement, counseling, mon-
itoring, and support) is a key component of timely HAART
initiation in order to avoid opportunistic infections, such as
cryptococcal meningitis. Scaling up of infrastructure to attend
356 braz j infect d i s . 2013;17(3):353–362
Table 1 – Key recommendations to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis.
Principles Recommendations
Early HIV diagnosis and treatment • Earlier HIV testing
• Improved access to HIV care
• Retention in care after HAART
Prevention • Pre-HAART CRAG screening in CD4<100 cells/L
• Preemptive ﬂuconazole treatment in those CRAG+
• Widespread prophylaxis not recommended
Optimized diagnostics • CRAG more sensitive than India ink. More rapid than culture
• CRAG LFA able to be implemented without laboratory infrastructure.
• Quantitative CSF cultures can quantify fungal burden and the response to therapy.
• Quantitative CSF microscopy is an alternative method to quantify fungal burden.
Optimized treatment • Induction therapy with amphotericin+5-FC. When it is not possible: amphotericin+ﬂuconazole
800–1200mg/day.
• IV ﬂuid and electrolyte (K, Mg) supplementation important during amphotericin administration
• Intracranial pressure control is a key component of treatment (see p. 15–16 and Fig. 3).
• Achieving and verifying CSF culture sterility is important. Alternatively, quantitative CSF microscopy
can predict culture status and guide when to switch to consolidation therapy.
e; IV,CRAG, cryptococcal antigen; LFA, lateral ﬂow assay; 5-FC, 5-ﬂucytosin
virus; HAART, highly active antiretroviral therapy.
HIV-infected patients who are not yet eligible for HAART is
observed in Latin America but is highly dependent on the par-
ticular public health system. Lost to HIV-care and death is
common prior to HAART initiation in low income-countries
and minimizing the delays within the formal health system
are essential.
Improving retention in care after HAART initiation
Antiretroviral therapy programs in low-income settings often
have retention-in-care of ∼60% of their patients at the end
of two years,53 with loss to follow-up as the major cause of
attrition, followed by death.53,54 However, a recent study per-
formed in rural Rwanda demonstrates that comprehensive
programs can have high retention rates (>90%) after two years
of care.55 Reasons for the high losses to follow-up include
transportation costs, food insecurity, user fees, drug stock-
outs, toxicities, pill burden, comorbidities, and psychosocial
reason like disclosure, stigma, and treatment fatigue.53,55
There is a need to identify innovative methods to sustain the
provision of long-term care for patients receiving HIV care. For
example, to decentralize the services by transferring patients
initiatingHIV care at tertiary centers (after stabilization) to pri-
mary care facilities closer to patients’ residencewith inclusion
of community-based approaches to HIV treatment. Improving
retention-in-care remains a worldwide challenge.
Access to care after HAART initiation
Although HAART treatment programs in low-income
countries have similar efﬁcacy rates to those reported in
high-income countries,56 mortality during the ﬁrst months
of treatment is higher in low-income countries.57 These
differences can be only partly explained by the lower CD4
cell counts and more advanced clinical stage. Cryptococcal
meningitis after introduction of HAART (related to immune
reconstitution or in patients with adherence problems) isintravenous; CSF, cerebrospinal ﬂuid; HIV, human immunodeﬁciency
a current challenge considering that access to prophylaxis,
diagnosis facilities, and effective treatment is often limited
in most low-income countries,57 including several from Latin
America. Thus, key strategies to address higher mortality
after HAART initiation in low-income countries include both
earlier HIV diagnosis and HAART initiation, and improving
access to and management of life-threatening opportunistic
infections, especially cryptococcal meningitis.58
Screening and preemptive treatment for subclinical
cryptococcosis
Several studies performed in Africa have reported the preva-
lence of detectable serum cryptococcal antigenemia between
2-12% in patients with CD4<100 cells/L entering into HIV
care. A positive serum cryptococcal antigen (CRAG+) when
starting HAART predicts the development of cryptococcal
meningitis, particularlywhen the CRAG titer is >1:8.59–61 Thus,
the use of routine serum or plasma CRAG screening in asymp-
tomatic HAART-naïve adults with CD4<100 cells/L, followed
by preemptive ﬂuconazole therapy can reduce the develop-
ment of cryptococcal meningitis and improve survival. The
World Health Organization (WHO) recommended preemptive
treatment for subclinical CRAG+ is ﬂuconazole 400mg twice
daily for two weeks followed by 400mg daily for eight weeks.43
This screen and treat strategy is highly cost-effective, and
is recommended by the WHO in locales where the preva-
lence of cryptococcal antigenemia is >3%.43,59 Although this
strategy has not been formally evaluated in Latin America,
epidemiological data suggest its potential beneﬁt and cost-
savings.1,25,61 Nevertheless, in centerswhere lumbar puncture
in readily available, asymptomatic patients with CRAG+ iden-
tiﬁed on screening, should likely have an lumbar puncture,
to exclude active disease. The use of point-of-care CRAG lat-
eral ﬂow assay (LFA) tests seems to be ideal for screening
for cryptococcosis, but there are no published data as
yet.
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rophylaxis for cryptococcal meningitis
he routine use of antifungal primary prophylaxis for cryp-
ococcal meningitis in HIV-infected patients with CD4 count
100 cells(L is not recommended prior to HAART in those
ho are CRAG-negative or where CRAG testing is unavailable,
nless a prolonged delay in HAART initiation is likely.43 While
ffective, primary prophylaxis is not recommended as this
pproach is less cost-effective than CRAG screening coupled
ith preemptive treatment.
ptimized diagnosis of cryptococcal meningitis
urrently, cryptococcalmeningitis diagnostics focus on: direct
SF examination by microscopy (India ink), CSF culture, or
ntigen detection using latex agglutination (LA) or enzyme
mmunoassay (EIA). The CRAG latex assay is a relatively
imple test that affords high sensitivity and speciﬁcity, but its
road use in Latin American is limited by the costs and by the
eed for laboratory infrastructure. Recently, an immunochro-
atographic CRAG lateral-ﬂow immunoassay (LFA), has been
eveloped as a point-of-care test for diagnosis of cryptococ-
osis (Immy Inc., Norman, Oklahoma, USA). This LFA test
s highly sensitive, inexpensive, and can be performed by
ntrained personnel in a point-of-care setting with results in
10min.62 In July 2011, the U.S. Food and Drug Administration
FDA) approved the CRAG LFA for use in serum and in April
012 for use in CSF. A recent study conﬁrmed the excellent
oncordance of LFA with traditional latex agglutination in
oth plasma and CSF samples.63 Countries should implement
idespread and reliable access to rapid diagnosis by either
ryptococcal antigen test.24 LFA cost is US$ 2 for low income
ountries and US$ 5 for middle and high income countries.
he LFA has greater applicability to the region as the assay can
e implemented without laboratory infrastructure or refriger-
tion of reagents. Local studies are expected in Latin America.
Response to treatment of cryptococcalmeningitis currently
s monitored by the use of CSF cultures in most reference
enters from Latin America. Quantitative cultures can iden-
ify fungal burden and the rate of clearance;28,29,49 however,
ny culture results have an intrinsic delay in reporting, and
uantitative cultures are not used in routine practice in Latin
merica. Thus, rapid and simple methods to estimate fun-
al burden remain clinically useful worldwide. Recently, we
eported quantitative CSF microscopy counting cryptococcal
easts per mcL of CSF was a useful intervention to predict CSF
ulture status and outcome. A baseline fungal burden of ≥10
easts/L of CSF by quantitative CSF microscopy was asso-
iated with a 15-fold higher odds of failing sterilize the CSF
y 7–14 days (p<0.001). Similarly, at 7–14 days, >10yeasts/L
f CSF was associated with continued positive CSF cultures
n 98% vs. 36% when <10yeasts/L of CSF (p<0.001).24 Thus,
his relatively simple tool could be used as a guide for when
o switch from intensive induction amphotericin therapy to
onsolidation ﬂuconazole monotherapy.ptimized treatment of cryptococcal meningitis
he importance of rapid CSF fungal clearance is supported
y an association between two-week culture status and3;17(3):353–362 357
10-week clinical outcome.49 The current recommended
standard of care is the use of combination antifungal ther-
apy during at least a 2-week induction phase.43,64 In Latin
America the most frequent treatment is monotherapy with
amphotericin B, as 5-FC is usually unavailable, and combined
therapy with amphotericin B and ﬂuconazole is as yet infre-
quent.
For the two week induction treatment phase, a reg-
imen containing amphotericin B combined with 5-FC is
recommended.43,64 Alternatively, the combination of ampho-
tericin B plus high doses of ﬂuconazole (800–1200mg/day in
divided doses) is recommendedwhere 5-FC is unavailable.43,64
This combination is supported by limited evidence in two
phase II clinical trials that showed a marginally superior
rate of CSF clearance with amphotericin B plus ﬂucona-
zole when compared with amphotericin alone,65 and similar
CSF early fungicidal activity with amphotericin plus ﬂu-
conazole 1200mg/day as with amphotericin plus 5-FC.47
In addition, in an open-label randomized clinical trial,
amphotericin combined with ﬂuconazole 800mg/day for
2-weeks results in superior but non-statistically differ-
ent outcomes as compared to treatment with 4-weeks
of amphotericin monotherapy.66 When giving ﬂuconazole
at doses above ≥800mg/day, we recommend to divide
the doses to reduce nausea.20 With induction therapy
with amphotericin B (0.7–1.0mg/kg/day) and ﬂuconazole
800mg/day, the expected average time to CSF sterilization
is 13.5 days based on the average early fungicidal activity
and median fungal burden present in Sub-Sahara African
studies.28–30,42,47,49,67,68
After induction therapy, the next phase is eight weeks
of consolidation treatment with ﬂuconazole monotherapy
at doses of 400–800mg/day. The differences in dosing is
related to the activity of ﬂuconazole, whereby doses of
400mg/day are fungistatic whereas doses ≥800mg/day are
fungicidal.30,67 In situations where the 2-week culture sta-
tus is as yet unknown, we recommend starting consolidation
therapy at 800mg/day of ﬂuconazole (in divided doses)
until the CSF culture is known to be sterile and until
HAART has been initiated. Once the CSF culture is known
to be sterile, consolidation therapy with 400mg/day of ﬂu-
conazole is likely sufﬁcient. Alternatively, quantitative CSF
microscopy could be used as a guide for when to switch
from intensive induction amphotericin therapy to consol-
idation ﬂuconazole monotherapy (400–800mg/day).24 After
completion of 8-weeks of consolidation therapy, secondary
prophylaxis as maintenance treatment phase with ﬂucona-
zole 200mg/day is recommended for at least one year anduntil
the CD4>200 cells/L.43,64
Recently, a WHO guideline recommended that patients
with amphotericin B-containing regimens should receive
a minimal package of toxicity prevention, monitoring, and
management to minimize serious complications, particularly
hypokalemia and nephrotoxicity.43 This package of care
includes pre-hydration with one L of normal saline coupled
with oral electrolyte supplementation with 40mEq daily of
potassium and 16mEq daily of magnesium. Although hydra-
tion prior amphotericin infusion is a commonpractice in Latin
America, the “preemptive” supplementation of potassium is
not used in most centers and could be incorporated in routine
i s . 20358 braz j infect d
clinical practice. This electrolyte supplementation is espe-
cially important in settingswith limited laboratorymonitoring
and/or delays in reporting of laboratory results. Liposomal
and lipid formulations of amphotericin are not available in
most public centers; however, when pre-hydration is used,
severe acute renal failure is relatively uncommon (<5%) in
most patients with cryptococcal meningitis. However, when
acute renal failure does occur or its risk is high, when possible,
liposomal/lipid formulations of amphotericin B should be
utilized.43 Where lipid formulations are unavailable, alterna-
tive options are early discontinuation of amphotericin coupled
with high dose ﬂuconazole 1200mg/day for 4-weeks.67,68 This
supplemental package of care is an important addition to
routine cryptococcal care to minimize amphotericin toxicity.
In Latin America, there are other unique considerations,
which are different than most countries from Sub-Saharan
Africa. In LatinAmerica, cerebral toxoplasmosis is the primary
cause of acute neurologic symptoms among HIV-infected
patients. Cranial nerve VI palsy is common with increased
intracranial pressure due to cryptococcalmeningitis; however,
other cranial nerve palsies very rare.28,69 Therefore, central
nervous system imaging should be performed before lumbar
puncture, particularly when there are localizing focal neuro-
logic deﬁcits present.
AlthoughpersonswithAIDS-related cryptococcalmeningi-
tis present with fewer cryptococcomas than non-HIV-infected
persons, other abnormal lesions (e.g. pseudocysts or dilated
Virchow-Robin spaces) are frequent,24,50 particularly with
magnetic resonance imaging (MRI), a more sensitive tech-
nique than computed tomography (CT).50 The presence of
these abnormal lesions is associated with worse prognosis.50
Disseminated cryptococcosis throughout the body and brain
is common, even when not clinically apparent. One his-
topathology study from Brazil reported a high frequency
of encephalitic involvement and focal brain lesions among
patients with cryptococcal meningitis.70 In many cases,
dissemination is often subclinical. Current recommenda-
tions suggest to prolong the induction treatment phase
in patients with cryptococcomas;64 however, there is little
evidence-based data to guide the treatment of other forms of
parenchymal involvement. Taken together, this information
and our unpublished data of cases observed in São Paulo, we
suggest that these cases must be treated similarly to crypto-
coccomas and clinical,microbiologic, and radiologic follow-up
are necessary for optimum management.
Increased ICP is frequent with cryptococcal meningitis,
and ICP management is an essential component of medical
care. Elevated ICP (≥25 cm H2O) is associated with reduced
short-term survival and impaired treatment response.71 For
these reasons, systematic and aggressive measures to con-
trol elevated ICP are critical and not to overlooked. Based
onpublished recommendations,9,43,64,71–73 the cornerstones of
management are summarized as follows. First, measure CSF
opening pressure at baseline with a manometer (in our set-
ting always after imaging); if the pressure is ≥25 cm H2O of
CSF and/or there are symptoms of increased ICP, drain ∼20mL
of CSF. Removal of more ﬂuid than necessary has the poten-
tial risk of a post lumbar puncture headache, whereas lack of
ICP control has a risk of death. Second, if there is persistent
value ≥25 cm H2O or symptoms, repeat therapeutic lumbar13;17(3):353–362
punctures daily until the CSF pressure and symptoms have
been stabilized for >2 days. Most patients require 2–3 lumbar
punctures for adequate control of ICP. One lumbar puncture
is rarely sufﬁcient (≤25% of patients) to control the ICP. When
in doubt (i.e. no manometer), we recommend to err on the
side of removal of too much CSF than too little, with 15–20mL
being an average amount removed in prospective studies
in Africa.28,69 Third, CSF examination should be repeated to
conﬁrm a therapeutic response (negative CSF culture by 14
days). Fourth, in the presence of persistently elevated ICP,
consider temporary external lumbar drainage, or alterna-
tively, external ventricular drainage, for persons who require
repeated daily lumbar puncture. Evaluate permanent shunt
(lumbar-peritoneal or, alternatively, ventricular-peritoneal) if
the patient is receiving or has received appropriate antifungal
therapy and if the standard methods of repeated therapeu-
tic lumbar punctures have failed to control the ICP. Ineffective
method of ICP control include: mannitol, acetazolamide, and
corticosteroids which are not supported nor recommended by
the available evidence.64 Fig. 3 displays the algorithm for the
management of elevated ICP of our institution.
Timing of HAART initiation
The optimal time to initiate HAART in AIDS-related cryptococ-
cal meningitis is undeﬁned. Although some studies showed
beneﬁts with earlier HAART initiation,74,75 only few cases of
cryptococcal meningitis were included in one of the trials.74
By contrast, a small randomized clinical trial compared early
HAART (≤72h after diagnosis) versus deferred HAART (≥10
weeks of treatment). In this study performed in Zimbabwe,
early initiation of HAART (stavudine, lamivudine, andnevirap-
ine) results in increasedmortalitywhen usedwith ﬂuconazole
800mg/day monotherapy as induction therapy.76 Despite sev-
eral limitations,77 this study suggests that very early initiation
may be harmful. Thus, HAART initiation should be deferred
until there is evidence of a sustained clinical response to
antifungal therapy. The WHO recommended timing of ART
initiation is after 2–4 weeks of induction and consolidation
treatment with amphotericin B-containing regimens com-
binedwithﬂucytosine or ﬂuconazole.43 Sterilizationof theCSF
prior to HAART initiation and before changing to 400mg of
ﬂuconazole consolidation therapy should be the goal. More
recently, a phase IV randomized clinical trial in Uganda
and South Africa investigating the optimal time to initiate
HAART (efavirenz-based) after amphotericin-based treatment
for cryptococcal meningitis (clinicaltrials.gov NCT01075152)
was halted early after 177 participantswere enrolled. Data and
safety monitoring board (DSMB) found a statistically higher
mortality among the participants randomized to early HAART
(median 8 days) compared with delayed HAART (median 5
weeks). This trial conﬁrms that early HAART in cryptococcal
meningitis does not have an overwhelming survival bene-
ﬁt and very well may be harmful.78 Based on our present
knowledge, HAART initiation should be delayed until comple-
tion of induction therapy with an objective to start HAART
within 4–5 weeks. Further delay beyond this timeframe is
likely unwarranted. Linkage to outpatient HIV care remains
a critical consideration for a delayed HAART strategy.79–81
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Initial opening ICP ≥ 25 cmH2O
With hydrocephalus
Ventriculo-peritoneal
shunt
Without hydrocephalus
Daily LP up to 7
consecutives day*
Normal ICP during > 2
consecutives days ICP persistantly high
Lumbar-
peritoneal
shunt
Maintain antifungal therapy and
weekly LP (measure of ICP, cultures)
Normal External lumbardrainage Abnormal
Continues treatment
Fig. 3 – Algorithm of management of intracranial pressure in AIDS-related cryptococcal meningitis. Emilio Ribas Institute of
Infectious Diseases, São Paulo, Brazil. LP, lumbar puncture; ICP, intracranial pressure; CT, computerized tomography.
* Alternatively, a temporary external lumbar drainage can be placed.
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ammune reconstitution inﬂammatory syndrome
apid restoration of immune function after starting HAART
eads to enhanced cell-mediated responses to live or dead
rganisms or shed Cryptococcus antigen that may present
s either (1) unmasking of subclinical infection in those who
re CRAG+ pre-HAART; or (2) recurrence of symptoms and
igns of previously identiﬁed and treated infection.82 Unmask-
ng IRIS can be prevented by pre-HAART CRAG screening
nd preemptive therapy. Unmasking cryptococcal disease
s extremely rare in persons who are pre-HAART CRAG-
egative. In persons with pre-HAART diagnosed cryptococcal
eningitis who respond to antifungal therapy and then
tart HAART, paradoxical IRIS can occur with recurrence of
eningitis symptoms or new non-CNS manifestations, such
s lymphadenopathy or pneumonitis.83 The average inci-
ence of paradoxical IRIS is 16% in one meta-analysis.84
n a Brazilian study this ﬁgure was 23%.85 Risk factors for
RIS-related cryptococcosis include a high baseline fungal
urden (i.e. fungemia and high serum cryptococcal anti-
en), failure to sterilize the CSF by 2-weeks, less initial
SF inﬂammation, lack of pro-inﬂammatory cytokine serum
esponses, low CD4 count (i.e. CD4<50 cells/L), and more
apid immune reconstitution.69,76,77,79–82,85,86 Symptoms usu-
lly develop early, at a median of 6-10 weeks after HAART
nitiation.82,85,87 Main neurologicmanifestations of cryptococ-
al IRIS reported in the literature include recurrent meningitis
ith or without increased ICP in the setting of sterile cultures
nd/or cryptococcomas.82,83,85 CSF cultures are consistently
82egative in paradoxical CM-IRIS.
Although the treatment of cryptococcal-related paradox-
cal IRIS is not completely understood, it is reasonable to
dminister systemic corticosteroids for severe life threateningmanifestations.82,83,87 Furthermore, serial lumbar punctures
are likely required to manage high ICP in these patients; how-
ever, discontinuation of HAART is usually unnecessary.82,83,85
Successful relief of symptoms by daily lumbar punctures was
conﬁrmed in a Brazilian case series.85 Similar approaches of
aggressive ICP control in IRIS have been used in Thailand. For
refractory paradoxical IRIS cases, anti-tumor necrosis factor
(TNF) agents have been anecdotally used, including thalido-
mide and anti-TNF monoclonal antibodies.88 Mortality at six
months may be similar or increased between IRIS and non-
IRIS patients.69,82,87 In Latin America, only one Brazilian study
about cryptococcal-related IRIS has been published.85 More
regional studies about this challenging problem are necessary.
Conclusions
Globally, Latin America represents the third region with most
cases of AIDS-related cryptococcal meningitis. Despite rele-
vant improvements during the HAART-era, this opportunistic
infection remains frequent and causes an unacceptable high
mortality in most countries. Urgent implementation of strate-
gies both on the public health level and individual care
level are necessary to reduce mortality and morbidity with
consideration of the local speciﬁc particularities and the het-
erogeneity of Latin America.Conﬂicts of interest
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